Nathaniel Lipkus Nathaniel Lipkus

Skinny drug labels and induced infringement: court decision creates divergence between U.S. and Canadian law

A recent U.S. Supreme Court decision solidifies U.S. case law on “skinny labelling”.

University tech transfer for startups

Nathaniel Lipkus, a partner in Osler’s Intellectual Property group provided practical insights into how startups can effectively engage with...

Can AI be an inventor on a patent or author of a copyrighted work?

Artificial intelligence (AI) proponents are testing the limits of today’s intellectual property laws. AI technologies, such as ChatGPT and DALL-E,...

Avoiding IP quicksand: lessons from ITP SA v. CNOOC Petroleum North America ULC

The decision serves as a reminder of the potential consequences of failing to manage IP diligently within large infrastructure projects.

The impact of stronger drug dosing patents on Canadian drug access

A consistent pain point and focus of reform within the system is the high cost of prescription drugs.

Curb your (lobbying) enthusiasm? Navigating Canada’s lobbying regulations – insights for the pharmaceutical industry

The interplay of legal frameworks, ethical considerations and diverse stakeholders make lobbying a complex and sensitive process.

Winning wellness: strategic IP and regulatory considerations in Canada’s booming natural health products industry

A strategic approach to intellectual property and regulatory vigilance can give companies a competitive edge in this rapidly growing industry.

U.K. appellate court rules artificial neural network application is not patent-eligible subject matter

Although artificial neural networks have evolved to form the backbone of modern commerce, their patentability remained unsettled.

PMPRB releases long-awaited draft guidelines regarding excessive drug pricing under new regime

The Patented Medicine Prices Review Board (PMPRB) has updated its approach to excessive pricing. Osler’s Nathaniel Lipkus and Yael Mansour discuss...